Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04981340
Other study ID # 43011
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 18, 2021
Est. completion date October 30, 2022

Study information

Verified date July 2021
Source University of Nis
Contact Vesna D Zivkovic, MD
Phone +381648839124
Email petvesna67@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

According to the 2016 International Children's Continence Society standardization of terminology of lower urinary tract function in children, dysfunctional voiding (DV) is a "urodynamic entity characterized by an intermittent and/or fluctuating uroflow rate due to involuntary intermittent contractions of the striated muscle of the external urethral sphincter or pelvic floor during voiding in neurologically normal individuals" . Symptoms vary from mild daytime frequency and urgency to daytime and nighttime wetting, pelvic holding maneuvers, voiding difficulties, urinary tract infections and vesicoureteral reflux (VUR). There are several ways of treating DV, including urotherapy, pharmacotherapy, surgery in the most severe cases, and even Botulinum toxin type A application in certain children. ''Urotherapy'' stands for non-surgical, non-pharmacologic treatment of lower urinary tract function and can be defined as a bladder re-education or rehabilitation program aiming at correction of filling and voiding difficulties. It involves the change of habits that a child has acquired during the period of toilet training and the development of motor control of the micturition reflex. Urotherapy starts with both parental and child education about the importance of regular hydratation and voiding, constipation treatment and genital hygiene. Together with this standard treatment, the pelvic floor muscle (PFM) retraining is initiated, and it includes pelvic floor exercises and various forms of biofeedback (visual, tactile, auditory, electromyography) with the same aim in mind - to help the child establish pelvic floor awareness and control, and relearn pelvic floor muscle relaxation. During the past decade, it has been shown that the PFMs are not an isolated unit, but a part of the abdominal capsule, which they form together with the diaphragm, superficial and deep abdominal muscles. As lower abdominal and PFM act synergistically, it is important that both be relaxed during voiding. Diaphragmatic breathing exercises are easy to learn and serve to teach the children abdominal relaxation.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date October 30, 2022
Est. primary completion date September 29, 2022
Accepts healthy volunteers No
Gender All
Age group 5 Years to 18 Years
Eligibility Inclusion Criteria: 1. Proven dysfunctional voiding according to the ICCS criteria 2. Signed informed consent by parents motivated to participate in the study 3. Previous treatment by pediatricians in primary care with timed voiding, hydratation and constipation management for three months with no significant success Exclusion Criteria: 1. Neurological disorders 2. Monosymptomatic nocturnal enuresis 3. Mental retardation 4. Structural abnormalities of the lower urinary tract -

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Diaphragmatic breathing
Same as previously described
Standard urotherapy
Same as previously described

Locations

Country Name City State
Serbia Medical Faculty Nis

Sponsors (1)

Lead Sponsor Collaborator
University of Nis

Country where clinical trial is conducted

Serbia, 

References & Publications (1)

Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebeke P, Rittig S, Walle JV, von Gontard A, Wright A, Yang SS, Nevéus T. The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children's Continence Society. Neurourol Urodyn. 2016 Apr;35(4):471-81. doi: 10.1002/nau.22751. Epub 2015 Mar 14. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of participants with cured or improved urinary incontinence, nocturnal enuresis, urinary tract infections and constipation at the end of the trial in each group of patients During the treatment period, all children in both groups will be asked to keep: a 48hr daytime frequency and volume chart, and a 7-day bladder and defecation diary. Children will be re-evaluated each month after the beginning of the therapy. The analysis of the diaries and charts will start with each visit to the Clinic, noticing changes in urinary incontinence, nocturnal enuresis, defecation frequency and urinary tract infections. 12 months
Primary Number of patients with improved uroflowmetry parameters and curve type Uroflowmetry with pelvic floor electromyography and post-void residual (PVR) urine measurement will be performed in both groups during monthly visits. It will be carried out twice as a child feels the need to void. PVR urine will be detected by ultrasound less than a minute after voiding. 12 months
Primary Number of patients with non-, partial and full response in both groups. Based on the clinical manifestations and uroflowmetry parameters, treatment result will be defined as full, partial and non-response. In children in whom urinary incontinence, nocturnal enuresis and urinary tract infections disappear entirely, treatment outcome will be described as "full response"; "partial response" when wetting episodes and urinary tract infections are reduced by more than 50%, and "non-response" when urinary incontinence, nocturnal enuresis and urinary tract infections persist. In children with constipation = 3 bowel movements per week, = 2 episodes of fecal incontinence per month and no abdominal pain with no laxative treatment for > 1 month will be classified as "full response". 12 months
Secondary Mean pre- and post-treatment Dysfunctional voiding and Incontinence Symptoms Score in children with non-, partial and full response in both groups. The Dysfunctional Voiding and Incontinence Scoring System will be completed at the beginning and the end of the 12-month treatment period. This questionnaire consists of 13 questions relating to daytime and nighttime wetting, degree of wetting, frequency of urination, voiding symptoms ( straining, intermittency), pain, urgency, urge incontinence, pelvic holding maneuvers, defecation frequency, and one question concerning the impact of voiding disorder on quality of life. Parents are expected to score the frequency and intensity of wetting during the day and night in the first four questions in the presence of their child, and the last eight questions are answered in a yes or no manner. Each answer, except the last question, is scored to produce a total score of between 0 and 35. The presence of voiding dysfunction (excluding quality of life score) in both genders is indicated by a total score of 9 or more. 12 months
Secondary Number of patients with pre-treatment score = 9 in children with non-/ partial and full response in both groups. In order to determine sensitivity and specificity of the initial and final score in predicting treatment outcome, all children will be divided in two groups. One group will consist of all children with full response, while the second group will consist of children with partial and non-response. Individual pre- and post-treatment total scores will be compared to the treatment outcome. 12 months
Secondary Number of patients with post-treatment score < 9 in children with non-/ partial and full response in both groups. 12 months
See also
  Status Clinical Trial Phase
Completed NCT01733290 - Botulinum Toxin Urethral Sphincter Injection for Dysfunctional Voiding Phase 2
Recruiting NCT06165731 - At-Home Diaphragmatic Interventions for Voiding Abnormalities (DIVA) N/A
Completed NCT06040333 - Dynamic Neuromuscular Stabilization Training in Dysfunctional Voiding N/A
Not yet recruiting NCT04147793 - Case Control Study to Investigate the Use of Urethral Pressure Profile Measurement in Children
Completed NCT05313984 - OptiLUTS Part C: The Development of a Symptom Assessment Tool in Sacral Neuromodulation.
Active, not recruiting NCT04490642 - Linguistic Validation of the Childhood Bladder and Bowel Dysfunction Questionnaire (CBBDQ) for 5-12 Years Old in Korean
Terminated NCT01465581 - Treatment of Neurogenic Incontinence by Surgery to Cut the Filum Terminale N/A
Completed NCT02806713 - The Effect of Oral PhenazopyrIdine on Perioperative Voiding After Mid-urethral sliNg (EPIPhANy Study) Phase 3